DOI: 10.57755/gzc8-9258
title: Hyperimmune serum containing Histophilus somni rHsp60, H.somni rOMP40 and Actinobacillus pleuropneumoniae LPS core oligosaccharide antibodies as supplementary treatment of respiratory tract diseases in dairy heifer calves.

description: <p class="MsoNormal" style="margin-bottom:0cm;line-height:150%"><span lang="EN-US" style="font-family:&#39;times new roman&#39; , serif">Bovine respiratory disease (BRD)
causes significant economic losses to the feedlot industry due to decreased
production and increased costs associated with treatment.</span><span lang="EN-GB" style="font-family:&#39;times new roman&#39; , serif">The pathogenesis of BRD involves stressful conditions, coupled with
viral infection, which results in suppressed immune defenses what led to the
bacteria proliferation in the upper respiratory tract. </span><span lang="EN-US" style="font-family:&#39;times new roman&#39; , serif">One of ways of
prevention and treatment of respiratory diseases is the administration of
antiserum. Hyperimmune serum is an important source of specific
antibodies.  The aim of this study was to produce bovine hyperimmune serum
containing antibody against selected conservative antigens of gram-negative
bacteria that present broad cross-reactivity with related antigens of many
strains of <em>Pasteurellaceae</em> and <em>Enterobacteriaceae </em>families and
evaluate the effect of supplementary application in the treatment of
respiratory tract infections in dairy heifer calves. </span><span lang="EN-GB" style="font-family:&#39;times new roman&#39; , serif">The
adjunctive administration of hyperimmune serum to antibiotic and nonsteroidal
anti-inflammatory drugs treatment of respiratory tract infections in dairy
heifer calves resulted in a reduction in the duration and severity of clinical
signs compared to calves treated without serum administration.</span></p><p class="MsoNormal" style="margin-bottom:0cm;line-height:150%"><span lang="EN-US" style="font-family:&#39;times new roman&#39; , serif"></span><br /></p><p><span lang="EN-US" style="line-height:107%;font-family:&#39;times new roman&#39; , serif;font-size:11pt"><br /></span><br /></p><p><br /></p>
description: <p class="MsoNormal" style="margin-bottom:0cm;line-height:150%"><span lang="EN-US" style="font-family:&#39;times new roman&#39; , serif">Bovine hyperimmune serum was
produced in cows immunized (six times) with three conservative antigens which
express broad cross-reactivity with several Gram-negative bacteria. The
composition contained recombinant 60 kDa heat shock protein from <em>Histophilus
somni</em> (<em>H. somni</em> rHsp60; 10 μg/dose), recombinant 40 kDa
outer-membrane protein from <em>H. somni</em> (<em>H. somni</em> rOMP40; 20
μg/dose), as well as <em>Actinobacilluspleuropneumoniae</em> LPS core
oligosaccharide conjugated with <em>H. somni</em> rHsp60 (20 μg/dose) and <em>Actinobacilluspleuropneumoniae</em>
LPS core oligosaccharide conjugated with rOMP40 (40 μg/dose). Antigens were
dissolved in 1.0 ml of saline containing 20% of Emulsigen® (MVP Technologies)
20% v/v as an adjuvant. From cows the serum samples were taken in: </span><span lang="EN-GB" style="font-family:&#39;times new roman&#39; , serif"></span></p><p class="MsoNormal" style="margin-bottom:0cm;line-height:150%"><span lang="EN-US" style="font-family:&#39;times new roman&#39; , serif">S1: serum samples collected
immediately before the first SC immunization</span><span lang="EN-GB" style="font-family:&#39;times new roman&#39; , serif"></span></p><p class="MsoNormal" style="margin-bottom:0cm;line-height:150%"><span lang="EN-US" style="font-family:&#39;times new roman&#39; , serif">S2-S5: serum samples collected
every two weeks immediately before next SC immunization</span><span lang="EN-GB" style="font-family:&#39;times new roman&#39; , serif"></span></p><p class="MsoNormal" style="margin-bottom:0cm;line-height:150%"><span lang="EN-US" style="font-family:&#39;times new roman&#39; , serif">S6: serum samples collected
immediately before last immunization (three weeks after fifth immunization)</span><span lang="EN-GB" style="font-family:&#39;times new roman&#39; , serif"></span></p><p class="MsoNormal" style="margin-bottom:0cm;line-height:150%"><span lang="EN-US" style="font-family:&#39;times new roman&#39; , serif">S7: serum collected three weeks
after last immunization</span><span lang="EN-GB" style="font-family:&#39;times new roman&#39; , serif"></span></p><p class="MsoNormal" style="margin-bottom:0cm;line-height:150%"><span lang="EN-US" style="font-family:&#39;times new roman&#39; , serif">In cow’s serum samples it was
evaluated the presence of:</span><span lang="EN-GB" style="font-family:&#39;times new roman&#39; , serif"></span></p><p class="MsoNormal" style="margin-bottom:0cm;line-height:150%"><strong><span lang="EN-US" style="font-family:&#39;times new roman&#39; , serif">a.</span></strong><span lang="EN-US" style="font-family:&#39;times new roman&#39; , serif">     
BoHV-1, BVDV, BRSV, PI-3V and <em>Mycoplasmabovis</em> antibodies </span><span lang="EN-GB" style="font-family:&#39;times new roman&#39; , serif"></span></p><p class="MsoNormal" style="margin-bottom:0cm;line-height:150%"><strong><span lang="EN-US" style="font-family:&#39;times new roman&#39; , serif">b.</span></strong><span lang="EN-US" style="font-family:&#39;times new roman&#39; , serif">    
anti-<em>H. somni</em> rOMP40, anti-<em>H. somni </em>rHsp60 and anti- <em>A.</em> <em>pleuropneumoniae</em>
LPS core oligosaccharide antibodies</span><span lang="EN-GB" style="font-family:&#39;times new roman&#39; , serif"></span></p><p class="MsoNormal" style="margin-bottom:0cm;line-height:150%"><span lang="EN-GB" style="font-family:&#39;times new roman&#39; , serif">At the
beginning of the treatment regimen, the calves were allocated to four groups (n
&#61; 10 per group)</span><span lang="EN-US" style="font-family:&#39;times new roman&#39; , serif">:</span><span lang="EN-GB" style="font-family:&#39;times new roman&#39; , serif"></span></p><p class="MsoNormal" style="margin-bottom:0cm;line-height:150%"><span lang="EN-US" style="font-family:&#39;times new roman&#39; , serif">CM: group treated without serum
with moderate signs of respiratory disease</span><span lang="EN-GB" style="font-family:&#39;times new roman&#39; , serif"></span></p><p class="MsoNormal" style="margin-bottom:0cm;line-height:150%"><span lang="EN-US" style="font-family:&#39;times new roman&#39; , serif">CS: group treated without serum
with severe signs of respiratory disease</span><span lang="EN-GB" style="font-family:&#39;times new roman&#39; , serif"></span></p><p class="MsoNormal" style="margin-bottom:0cm;line-height:150%"><span lang="EN-US" style="font-family:&#39;times new roman&#39; , serif">EM: group treated with serum with
moderate signs of respiratory disease</span><span lang="EN-GB" style="font-family:&#39;times new roman&#39; , serif"></span></p><p class="MsoNormal" style="margin-bottom:0cm;line-height:150%"><span lang="EN-US" style="font-family:&#39;times new roman&#39; , serif">ES: group treated with serum with
severe signs of respiratory disease</span><span lang="EN-GB" style="font-family:&#39;times new roman&#39; , serif"></span></p><p class="MsoNormal" style="margin-bottom:0cm;line-height:150%"><span lang="EN-US" style="font-family:&#39;times new roman&#39; , serif">From calves the serum samples were
taken in:</span><span lang="EN-GB" style="font-family:&#39;times new roman&#39; , serif"></span></p><p class="MsoNormal" style="margin-bottom:0cm;line-height:150%"><span lang="EN-US" style="font-family:&#39;times new roman&#39; , serif">SS1: serum samples collected before
treatment</span><span lang="EN-GB" style="font-family:&#39;times new roman&#39; , serif"></span></p><p class="MsoNormal" style="margin-bottom:0cm;line-height:150%"><span lang="EN-US" style="font-family:&#39;times new roman&#39; , serif">SS2: serum samples collected on the
7th day after treatment</span><span lang="EN-GB" style="font-family:&#39;times new roman&#39; , serif"></span></p><p class="MsoNormal" style="margin-bottom:0cm;line-height:150%"><span lang="EN-US" style="font-family:&#39;times new roman&#39; , serif">SS3: serum samples collected on the
14th day after treatment</span><span lang="EN-GB" style="font-family:&#39;times new roman&#39; , serif"></span></p><p class="MsoNormal" style="margin-bottom:0cm;line-height:150%"><span lang="EN-US" style="font-family:&#39;times new roman&#39; , serif">SS4: serum samples collected at 6
months of age</span><span lang="EN-GB" style="font-family:&#39;times new roman&#39; , serif"></span></p><p class="MsoNormal" style="margin-bottom:0cm;line-height:150%"><span lang="EN-US" style="font-family:&#39;times new roman&#39; , serif">The harvested serum was
administered subcutaneously to dairy heifer calves on the initial day of
treatment for respiratory diseases, as an adjunct to antibiotics and
anti-inflammatory drugs.</span><span lang="EN-GB" style="font-family:&#39;times new roman&#39; , serif"></span></p><p class="MsoNormal" style="margin-bottom:0cm;line-height:150%"><span lang="EN-US" style="font-family:&#39;times new roman&#39; , serif">Health status was estimated on a
point scale according to the modified calf health scale system on days 1, 7 and
14th of treatment.</span><span lang="EN-GB" style="font-family:&#39;times new roman&#39; , serif"></span></p><p class="MsoNormal" style="margin-bottom:0cm;line-height:150%"><span lang="EN-US" style="font-family:&#39;times new roman&#39; , serif">In calves&#39; serum samples, the
following parameters were evaluated:</span><span lang="EN-GB" style="font-family:&#39;times new roman&#39; , serif"></span></p><p class="MsoNormal" style="margin-bottom:0cm;line-height:150%"><span lang="EN-US" style="font-family:&#39;times new roman&#39; , serif">a.      
Acute phase proteins (APP), including fibrinogen, serum haptoglobin, and serum
amyloid A concentrations</span><span lang="EN-GB" style="font-family:&#39;times new roman&#39; , serif"></span></p><p class="MsoNormal" style="margin-bottom:0cm;line-height:150%"><span lang="EN-US" style="font-family:&#39;times new roman&#39; , serif">b.     
 Immunoglobulin (Ig) concentrations, specifically IgG1, IgG2, and IgM</span><span lang="EN-GB" style="font-family:&#39;times new roman&#39; , serif"></span></p><p class="MsoNormal" style="margin-bottom:0cm;line-height:150%"><span lang="EN-GB" style="font-family:&#39;times new roman&#39; , serif"> c.       The presence of antibodies against BoHV-1, BRSV, BVDV, PI-3V, and <em>Mycoplasma
bovis</em></span></p><p class="MsoNormal" style="margin-bottom:0cm;line-height:150%">

















































<br /></p><p class="MsoNormal" style="margin-bottom:0cm;line-height:150%"><span lang="EN-GB" style="font-family:&#39;times new roman&#39; , serif"> </span><br /></p><p class="MsoNormal" style="margin-bottom:0cm;line-height:150%"><br /></p>